Craft

Biohaven

Stock Price

$51

2024-10-29

Market Capitalization

$5.2 B

2024-10-29

Biohaven Summary

Company Summary

Overview
Biohaven (also known as SpinCo, formerly known as Biohaven Research) is a biopharmaceutical company that develops therapies for diseases such as migraine, depression, bipolar, and schizophrenia. Its research programs focus on therapies with target indications, including epilepsy, mood disorders, OCD, SCA, SMA, and pain disorders. The key clinical programs include Kv7 Activator, Glutamate, Myostatin, and ARM.
Type
Public
Status
Active
Founded
2022
HQ
New Haven, CT, US | view all locations
Website
https://www.biohaven.com/
Sectors

Key People

  • Vlad Coric

    Vlad Coric, Chairman & Chief Executive Officer

  • Matthew Buten

    Matthew Buten, Chief Financial Officer

  • Cliff Bechtold

    Cliff Bechtold, President & General Manager, Biohaven Ireland, Chief Compliance Officer

  • Kimberly Gentile

    Kimberly Gentile, Senior Vice President, Clinical Operations

LocationsView all

2 locations detected

  • New Haven, CT HQ

    United States

    215 Church St

  • Road Town, Tortola

    Virgin Islands (British)

    P.O. Box 173

Biohaven Financials

Summary Financials

Net income (Q1, 2026)
($130.5M)
Cash (Q1, 2026)
$273.1M
EBIT (Q1, 2026)
($130.4M)
Enterprise value
$5.2B

Footer menu